Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Abstract Adolescents (12–17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on maintenance therapy in patients with severe eosinophilic asthma ≥ 6 years of age in...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2019-09-01
|
| Col·lecció: | Allergy, Asthma & Clinical Immunology |
| Matèries: | |
| Accés en línia: | http://link.springer.com/article/10.1186/s13223-019-0366-x |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|